JohnMcevoyBurkeMD

Oncology • Parker, CO

Genitourinary Oncology, Hematologic Oncology

Physician

Join to view full profile

Dr. Burke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Burke's full profile

Already have an account?

Office
9397 Crown Crest Blvd
Ste 421
Parker, CO 80138
Phone+1 303-805-7744

Fax+1 720-851-4141

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
University of California (San Francisco)Residency, Internal Medicine, 1997 - 2000
Baylor College of MedicineClass of 1997

Certifications & Licensure

CA State Medical License 1999 - Present
CO State Medical License 2003 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
Completed
Phase 1
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Start of enrollment: 2018 Oct 29
Terminated
Phase 1
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Start of enrollment: 2020 Nov 12
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01
13 citations
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.
Aaron T Gerds, Ruben Mesa, John M Burke, Michael R Grunwald, Brady L Stein
Blood. 2024-04-18
Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
Tycel Phillips, Nicholas Liu, Brian Bloudek, Kristen Migliaccio-Walle, Jade Reynolds
Journal of Managed Care & Specialty Pharmacy. 2023-12-01

Abstracts/Posters

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezom...
John M Burke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...
John M Burke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma
John M Burke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
John M Burke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB St...
John M Burke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
John M Burke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patie...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Community Cancer Practices Implement Venetoclax Protocols for CLL, but Gaps RemainDecember 8th, 2024
$Entospletinib Falls Short in relapsed/refractory DLBCL$
Entospletinib Falls Short in relapsed/refractory DLBCLOctober 11th, 2018
Patient Power Cll FatigueJanuary 13th, 2019
Join now to see all